Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Sanofi

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Sanofi's 2013 sales performance.

Sanofi

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second Sarclisa combination regimen for multiple myeloma approved in EU

Sanofi’s Sarclisa has received approval from the European Commission to treat patients with relapsed multiple myeloma who have received at least one prior therapy. ... The carfilzomib and dexamethasone [Sarclisa] combination represents an important

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses months when compared to Sanofi’s Aubagio (teriflunomide) in a subgroup of newly diagnosed, treatment-naive patients with relapsing multiple sclerosis (RMS). ... The approval was based on results from the phase 3 ASCLEPIOS I and II studies, in which

Sanofi pays $160m upfront to acquire Tidal Therapeutics

Sanofi pays $160m upfront to acquire Tidal Therapeutics Sanofi has paid $160m upfront to acquire Tidal, with up to $310m contingent on the achievement of future milestones. ... In a statement, Sanofi said the initial applications are targeting specific types of immune cells,.

Novartis gains EU approval for relapsing MS drug Kesimpta

Novartis gains EU approval for relapsing MS drug Kesimpta 2021. The approval is based on results from the phase 3 ASCLEPIOS I and II studies, in which Kesimpta (ofatumumab) demonstrated superiority over Sanofi’s Aubagio (teriflunomide) in reducing the number

J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval

J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval The EU marketing authorisation application for the S1P1 modulator is based on data from the phase 3 OPTIMUM trial, designed to evaluate the efficacy of once daily oral Ponvory versus

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics